Rasio cepet Clene Inc. (CLNN)

Clene Inc. (CLNN) is developing a unique nanotherapy system for multiple sclerosis and ALS, utilizing patented gold crystals to block generics. This chart reflects an asset value of 3.20, while patients with paralysis are actively enrolling in CNM-Au8 trials due to a lack of alternatives. However, the business's viability currently relies exclusively on investor capital and FDA verdicts.

For Clene Inc., which develops gold nanocrystal-based drugs funded by grants, the quick ratio serves as a survival indicator during the clinical trial period. This metric compares the sum of cash and accounts receivable against current liabilities, excluding illiquid inventories, allowing for an assessment of the company's ability to settle debts without the emergency sale of assets.